Trinity Biotech (NASDAQ: TRIB) is one of 24 public companies in the “Diagnostic substances” industry, but how does it compare to its competitors? We will compare Trinity Biotech to related businesses based on the strength of its earnings, institutional ownership, profitability, dividends, valuation, analyst recommendations and risk.
Earnings & Valuation
This table compares Trinity Biotech and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Trinity Biotech||$99.14 million||$2.30 million||19.54|
|Trinity Biotech Competitors||$308.35 million||$18.66 million||-39.62|
This is a summary of current ratings for Trinity Biotech and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Trinity Biotech Competitors||101||367||567||19||2.48|
As a group, “Diagnostic substances” companies have a potential upside of 15.07%. Given Trinity Biotech’s competitors higher probable upside, analysts clearly believe Trinity Biotech has less favorable growth aspects than its competitors.
Risk & Volatility
Trinity Biotech has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, Trinity Biotech’s competitors have a beta of 1.44, suggesting that their average stock price is 44% more volatile than the S&P 500.
Insider and Institutional Ownership
62.1% of Trinity Biotech shares are held by institutional investors. Comparatively, 53.6% of shares of all “Diagnostic substances” companies are held by institutional investors. 12.7% of Trinity Biotech shares are held by company insiders. Comparatively, 13.5% of shares of all “Diagnostic substances” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares Trinity Biotech and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Trinity Biotech Competitors||-884.88%||-64.84%||-17.51%|
About Trinity Biotech
Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine. It operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business. Trinity Biotech’s blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections.
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.